Title : BacLI: A potential antibacterial agent against hospital-acquired lung infection
Abstract:
Hospital-acquired infections are infections that are not present at the time of admission to a hospital and thus include ventilator-associated pneumonia, hospital-acquired pneumonia, etc. Hospital-acquired pneumonia (HAP), also known as nosocomial pneumonia, is a lower respiratory bacterial infection that occurs 48 hours or more after hospital admission and does not appear due to intubation at the time of admission. Lung infection is a situation where a disease-causing microorganism causes damage and inflammation in the Lung airways or tissues caused by the accumulation of immune cells.There are a number of symptoms that are common with lung infections, and they can occur regardless of the type of infection.
Breathing difficulties, chest congestion, and back pain are all common symptoms. Hospital-acquired pneumonia (HAP) is typically caused by bacteria, especially aerobic gram-negative bacilli, such as Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumonia, and Acinetobacter species.Lung Infection is a very common sort of infection that will affect many generations irrespective of age, gender and the treatment which are available have very toxic side effects antibiotic resistance is also very common, and to control lung infection strong antibiotics have to be given and these antibiotics have very severe toxic effects on several parts of the body. We are providing a solution for hospital-acquired lung infections.
By using a potential antimicrobial agent i.e Bacteriocin, Bacteriocins offer great potential in a wide range of fields around the world, and both the medical and agricultural industries are conducting research on the use of bacteriocins as therapeutic agents. Bacteriocins have become an alluring tool for human health because they are ribosomal–synthesized antibacterial molecules of a protein family that inhibit growth and have the ability to eliminate certain microorganisms and are highly potent, exhibit antimicrobial activity at nanomolar concentrations, and are harnessed for designing safer and better therapies for mankind.
In addition to the discovery of bacteriophages and the development of antibiotics, bacteriocins did not receive the same level of attention as antibiotics due to a lack of understanding of their biology, which resulted in difficulties in production and inconsistent control of microbial growth. Bacteriocins are a very potent and effective alternative to strong antibiotics for the treatment of Hospital Acquired Lung infections as the antibiotics cause many undesirable side effects. Bacteriocins are protein in their nature and when taken orally will be cleaved by stomach proteases. So, drug resistance problems could be not be an issue with bacteriocin.
Audience Take Away:
- This presentation will open a window of thought for the treatment of hospital acquired infections particularly lung infections because the bacteria have developed resistance against the available antibiotics that makes this difficult to treat.
- After discussing the unique properties and approach in presentation the audience will be benefited by acquiring new approach to save the life of patient.
